https://www.fool.com/investing/general/2013/12/18/how-gleevec-changed-the-game-for-novartis.aspx
https://www.fool.com/investing/general/2014/04/30/cannavest-what-investors-need-to-watch.aspx
https://www.fool.com/investing/general/2013/09/25/strykers-shocking-move-for-mako-surgical.aspx
https://www.fool.com/investing/general/2014/01/02/are-pharma-companies-too-big-to-innovate.aspx
https://www.fool.com/investing/general/2013/09/29/is-pfizers-oncology-division-poised-to-grow.aspx
https://www.fool.com/investing/general/2013/09/27/time-to-panic-about-mercks-patent-expirations.aspx
https://www.fool.com/investing/general/2014/06/04/why-is-intel-partnering-with-a-company-youve-proba.aspx
https://www.fool.com/investing/general/2013/09/26/3-dividends-investors-love.aspx
https://www.fool.com/investing/general/2014/04/23/whats-behind-the-biotech-crash.aspx
https://www.fool.com/investing/general/2013/11/29/teva-stock-3-key-things-to-know.aspx
https://www.fool.com/investing/general/2013/10/06/can-this-obesity-drugmaker-beat-arena-and-vivus-to.aspx
https://www.fool.com/investing/general/2013/10/18/what-was-behind-anacors-28-climb.aspx
https://www.fool.com/investing/general/2014/05/31/the-connected-tv.aspx
https://www.fool.com/investing/general/2013/10/16/abbotts-earnings-made-easy.aspx
https://www.fool.com/investing/general/2013/12/13/will-obamacare-crush-these-health-care-giants.aspx
https://www.fool.com/investing/general/2014/03/03/4-keys-to-vertex-pharmaceuticals-success.aspx
https://www.fool.com/investing/general/2014/01/29/sanofi-stock-will-this-be-a-big-pharma-winner-in-2.aspx
https://www.fool.com/investing/general/2013/10/03/omeros-corporations-eye-popping-surge.aspx
https://www.fool.com/investing/general/2013/09/26/3-reasons-behind-rite-aids-incredible-run.aspx
https://www.fool.com/investing/general/2013/11/14/motley-fool-co-founder-david-gardners-approach-to.aspx
https://www.fool.com/investing/general/2013/12/01/3-drugs-that-changed-medicine-and-were-discovered.aspx
https://www.fool.com/investing/general/2014/03/18/better-buy-netflix-vs-gilead-sciences.aspx
https://www.fool.com/investing/general/2014/02/03/astrazeneca-stock-1-red-light-1-green-light.aspx
https://www.fool.com/investing/general/2014/03/28/an-interview-with-portola-pharmaceuticals-ceo-bill.aspx
https://www.fool.com/investing/general/2014/01/09/red-light-green-light-2-things-to-know-before-buyi.aspx
https://www.fool.com/investing/general/2013/09/25/3-reasons-to-sell-bristol-myers-squibb.aspx
https://www.fool.com/investing/general/2014/03/24/better-buy-consol-energy-vs-gilead-sciences.aspx
https://www.fool.com/investing/general/2013/10/30/down-8-whats-behind-tevas-massive-plunge.aspx
https://www.fool.com/investing/general/2013/09/25/market-checkup-september-25.aspx
https://www.fool.com/investing/general/2013/11/25/kickstarter-and-the-long-tail.aspx
https://www.fool.com/investing/general/2016/05/23/drawing-biopharma-concepts-with-a-crayon.aspx
https://www.fool.com/investing/general/2013/12/15/what-will-the-fitbit-look-like-in-5-years.aspx
https://www.fool.com/investing/general/2014/03/07/the-spark-of-innovation-at-vertex-pharmaceuticals.aspx
https://www.fool.com/investing/general/2013/09/24/can-merck-recover-from-this-fda-rejection.aspx
https://www.fool.com/investing/general/2013/11/29/astrazeneca-stock-3-things-to-know.aspx
https://www.fool.com/investing/general/2014/04/10/biotech-banter-fda-delay-clinical-trial-news-and-t.aspx
https://www.fool.com/investing/general/2013/10/28/another-win-for-big-biotech-biogen.aspx
https://www.fool.com/investing/general/2014/05/20/an-interview-with-harry-kirsch-cfo-of-novartis.aspx
https://www.fool.com/investing/general/2014/06/04/will-your-car-have-no-steering-wheel-in-5-years-go.aspx
https://www.fool.com/investing/general/2014/02/14/why-novartis-is-one-of-todays-most-innovative-comp.aspx
https://www.fool.com/investing/general/2013/11/23/three-sources-of-investment-ideas-from-motley-fool.aspx
https://www.fool.com/investing/general/2014/01/07/roches-genentech-and-the-culture-of-innovation.aspx
https://www.fool.com/investing/general/2014/06/17/better-stock-today-challenge-apple-vs-annaly-capit.aspx
https://www.fool.com/investing/general/2013/09/26/should-merck-copy-pfizer-and-join-the-spinoff-club.aspx
https://www.fool.com/investing/general/2014/01/29/eli-lilly-and-company-stock-1-red-light-1-green-li.aspx
https://www.fool.com/investing/general/2014/03/21/better-buy-enterprise-products-partners-vs-amgen.aspx
https://www.fool.com/investing/general/2014/06/05/facebook-incs-whatsapp-and-microsoft-corporations.aspx
https://www.fool.com/investing/general/2014/01/02/why-big-pharma-companies-need-to-collaborate.aspx
https://www.fool.com/investing/general/2014/01/14/why-biotech-boomer-intercept-pharmaceuticals-inc-t.aspx
https://www.fool.com/investing/general/2013/09/24/3-catalysts-bristol-myers-squibb-investors-need-to.aspx
https://www.fool.com/investing/general/2013/09/26/what-was-behind-pacific-biosciences-70-pop.aspx
https://www.fool.com/investing/general/2013/11/19/invest-in-what-you-know-maybe-maybe-not.aspx
https://www.fool.com/investing/general/2013/12/15/obamacares-latest-enrollment-numbers-good-news-or.aspx
https://www.fool.com/investing/general/2014/05/30/att-inc-dips-its-toes-in-the-connected-home.aspx
https://www.fool.com/investing/general/2013/09/30/2-stocks-to-watch-as-obamacare-exchanges-roll-out.aspx
https://www.fool.com/investing/general/2014/06/02/will-googles-nest-disrupt-the-smart-home-industry.aspx
https://www.fool.com/investing/general/2014/02/04/medicine-and-gaming-the-surprising-link-you-probab.aspx
https://www.fool.com/investing/general/2014/02/10/big-pharma-diversification-a-winning-model-or-reci.aspx
https://www.fool.com/investing/general/2014/02/27/from-startup-to-billion-dollar-biotech-an-inside-l.aspx
https://www.fool.com/investing/general/2013/10/18/what-was-behind-ariads-40-drop.aspx
https://www.fool.com/investing/general/2014/03/16/3-prescription-drugs-you-didnt-know-come-from-mari.aspx
https://www.fool.com/investing/general/2013/10/16/the-bear-and-bull-cases-for-amarin.aspx
https://www.fool.com/investing/general/2014/06/18/better-stock-today-challenge-invensense-vs-distrib.aspx
https://www.fool.com/investing/general/2014/01/10/down-29-why-chelsea-therapeutics-international-ltd.aspx
https://www.fool.com/investing/general/2013/10/18/the-next-cholesterol-fighting-blockbuster-drug.aspx
https://www.fool.com/investing/general/2013/11/24/how-investors-can-look-beyond-the-numbers.aspx
https://www.fool.com/investing/general/2013/12/17/is-culture-the-solution-to-big-pharmas-innovation.aspx
https://www.fool.com/investing/general/2014/05/28/understanding-multiple-sclerosis-an-interview-with.aspx
https://www.fool.com/investing/general/2013/10/11/down-20-ariad-pharmaceuticals-second-dose-of-bad-n.aspx
https://www.fool.com/investing/general/2014/01/31/can-teva-rebound-after-this-rejection.aspx
https://www.fool.com/investing/general/2013/09/25/the-details-behind-mako-surgicals-80-pop.aspx
https://www.fool.com/investing/general/2014/01/14/up-140-why-chelsea-therapeutics-international-ltd.aspx
https://www.fool.com/investing/general/2014/06/17/better-stock-today-challenge-invensense-vs-sodastr.aspx
https://www.fool.com/investing/general/2014/01/10/up-61-why-intercept-pharmaceuticals-inc-popped-aga.aspx
https://www.fool.com/investing/general/2013/12/13/merck-stock-3-key-things-to-watch-now.aspx
https://www.fool.com/investing/general/2013/10/28/why-this-dow-heavyweight-sank-on-earnings.aspx
https://www.fool.com/investing/general/2013/12/18/sanofi-the-most-successful-comeback-in-big-pharma.aspx
https://www.fool.com/investing/general/2013/12/15/will-wearable-technology-be-the-next-big-innovatio.aspx
https://www.fool.com/investing/general/2013/10/06/the-government-shutdown-wont-stop-this-fda-meeting.aspx
https://www.fool.com/investing/general/2014/02/13/marijuana-stocks-a-real-investing-opportunity-or-n.aspx
https://www.fool.com/investing/general/2014/06/20/better-stock-today-challenge-invensense-vs-seadril.aspx
https://www.fool.com/investing/general/2014/06/15/better-stock-today-invensense-vs-johnson-johnson.aspx
https://www.fool.com/investing/general/2014/06/15/better-stock-today-vanguard-natural-resources-vs-a.aspx
https://www.fool.com/investing/general/2014/01/13/the-3-worst-performing-big-pharma-stocks-of-2013-l.aspx
https://www.fool.com/investing/general/2013/12/31/how-mobile-technology-is-changing-medicine-as-we-k.aspx
https://www.fool.com/investing/general/2014/02/27/ask-a-fool-what-is-your-foolish-opinion-of-horizon.aspx
https://www.fool.com/investing/general/2013/11/27/motley-fool-david-gardner-investing-for-beginners.aspx
https://www.fool.com/investing/general/2013/11/19/should-you-fear-stocks-in-the-health-care-space.aspx
https://www.fool.com/investing/general/2013/11/26/novo-nordisks-biggest-strength-and-weakness.aspx
https://www.fool.com/investing/general/2013/10/30/down-13-more-bad-luck-for-amarin-corporation-plc.aspx
https://www.fool.com/investing/general/2014/03/20/ranking-big-pharmas-top-drugs-of-2013.aspx
https://www.fool.com/investing/general/2013/09/26/abbvies-3-biggest-opportunities.aspx
https://www.fool.com/investing/general/2014/03/22/better-buy-gilead-sciences-vs-berkshire-hathaway.aspx
https://www.fool.com/investing/general/2013/12/15/can-mobile-gaming-help-save-lives-3.aspx
https://www.fool.com/investing/general/2014/01/06/the-5-best-performing-big-pharma-stocks-of-2013-bm.aspx
https://www.fool.com/investing/general/2013/12/11/what-oncomeds-deal-with-celgene-means-for-investor.aspx
https://www.fool.com/investing/general/2013/12/18/glaxosmithkline-the-worlds-biggest-biotech-startup.aspx
https://www.fool.com/investing/general/2014/06/09/this-internet-of-things-company-is-changing-medici.aspx
https://www.fool.com/investing/general/2014/02/11/dividend-stock-to-watch-today-sanofi-sa-adr.aspx
https://www.fool.com/investing/general/2014/04/23/allergan-inc-another-billion-dollar-buy-out-target.aspx
